Clinical Practicum Sample Clauses

Clinical Practicum. During the clinical rotation training experiences, students perform hands-on advanced clinical training tasks under the supervision of an on-site clinical preceptor. The MLS Program and the student work together in identifying an appropriate clinical laboratory that will serve as a clinical training site. In some cases, more than one clinical training site may be needed to ensure all required competencies are taught and assessed. Training usually occurs on the first shift. Students may need to revise their work schedule or take time-off to complete clinical hours. Admission Period: Southwestern Community College students must be admitted to the UC College of Allied Health Sciences during the duration of this agreement (i.e. between March 2021 and March 2024). Agreement Execution Date: March 2021 Agreement End Date: March 2024 TRANSFER ARTICULATION AGREEMENT Southwestern Community College, Associate of Applied Science, Medical Laboratory Technology to University of Cincinnati, College of Allied Health Sciences, Bachelor of Science in Medical Laboratory Science (ONLINE)
Sample 1See All (5)
AutoNDA by SimpleDocs
Clinical Practicum. During the clinical rotation training experiences, students perform hands-on advanced clinical training tasks under the supervision of an on-site clinical preceptor. The MLS Program and the student work together in identifying an appropriate clinical laboratory that will serve as a clinical training site. In some cases, more than one clinical training site may be needed to ensure all required competencies are taught and assessed. Training usually occurs on the first shift. Students may need to revise their work schedule or take time-off to complete clinical hours. TRANSFER ARTICULATION AGREEMENT Xxxxx State College, Associate of Applied Science, Medical Laboratory Technology to University of Cincinnati, College of Allied Health Sciences, Bachelor of Science in Medical Laboratory Science (ONLINE) Admission Period: Xxxxx State College students must be admitted to the UC College of Allied Health Sciences during the duration of this agreement (i.e. between May 2022 and May 2025). Agreement Execution Date: May 2022 Agreement End Date: May 2025 EXECUTION, DURATION AND REVIEW OF AGREEMENT: Primary Contact Person for this Agreement: TRANSFER ARTICULATION AGREEMENT
Sample 1Sample 2
Clinical Practicum. School shall be responsible for the development, implementation, and operation of the clinical component of its educational programs offered and conducted at CoxHealth pursuant to this Agreement (collectively referred to herein as the “Practicum”). Such responsibilities of School include the following: a. Maintain responsibility for the educational curriculum and learning environment for Students including providing practical instruction to Students prior to their clinical assignments at CoxHealth; b. Appoint qualified faculty or indicate appropriate preceptors/supervisors responsible for guiding the Students’ experiences; c. Assign to CoxHealth only those Students who have satisfactorily completed the prerequisites for clinical experience; d. Determine by mutual consent of CoxHealth and School the dates and times for Student placement and School must notify CoxHealth in advance of its planned schedule of Student assignments, including the dates of assignments, number of Students participating, and type of educational experience expected; e. Acquaint CoxHealth personnel with the overall objectives of the School and provide the appropriate educational objectives and documents for clinical experiences to CoxHealth; f. Participate in the supervision of Students and performance at CoxHealth including assuming responsibility for ensuring that both Students and faculty/supervisors comply with CoxHealth’s rules and regulations; g. Maintain all records regarding Students’ experiences.
Sample 1Sample 2
Clinical Practicum. During the clinical rotation training experiences, students perform hands-on advanced clinical training tasks under the supervision of an on-site clinical preceptor. The MLS Program and the student work together in identifying an appropriate clinical laboratory that will serve as a clinical training site. In some cases, more than one clinical training site may be needed to ensure all required competencies are taught and assessed. Training usually occurs on the first shift. Students may need to revise their work schedule or take time-off to complete clinical hours. Admission Period: Northeast Mississippi Community College students must be admitted to the UC College of Allied Health Sciences during the duration of this agreement (i.e. between September 2022 and August 2025). Agreement Execution Date: September 2022 Agreement End Date: August 2025 TRANSFER ARTICULATION AGREEMENT Northeast Mississippi Community College, Associate of Applied Science, Medical Laboratory Technology to University of Cincinnati, College of Allied Health Sciences, Bachelor of Science, Medical Laboratory Science (ONLINE)
Sample 1
Clinical Practicum. The required clinical practicum is referred to as competency-based education. The curriculum is structured based on defined objectives and competencies. Clinical education is a planned and structured experience. The entire 20-month program is an inter-sequential integration of didactic and practical learning through classroom lectures, clinical laboratories, supplementary lectures, discussions, demonstrations, and supervised practice of standardized procedures. Clinical sites may be added or deleted at the discretion of the program director and faculty AND based on the JRCERT recognition process. Each student has access to clinical facilities that offer a balanced education sufficient in quantity and variety of MRI examinations as well as diversified modern equipment. A standardized evaluation system is followed through documentation of a student’s clinical progress for the purpose of providing developmental assistance in correcting weaknesses. All students are required to demonstrate their competence in a variety of procedures and tasks. School faculty makes every effort to preserve educational cohesiveness without compromising the patient care responsibility of the Magnetic Resonance Imaging department. The program faculty schedules each student to practice individually with registered MRI technologists to ensure close direct or indirect supervision and to permit the student to obtain more than ample experience in all practical phases of routine, specialized, and emergency clinical functions. A 1:1 student to magnet ratio is maintained at all times. Clinical schedules are posted by the Educational Coordinator. The program faculty has the right to make changes to the clinical assignment schedule if deemed necessary or advantageous. A student will never be expected to replace a registered technologist.
Sample 1
Clinical Practicum. The required clinical practicum is referred to as competency-based education. The curriculum is structured based on defined objectives and competencies. Clinical education is a planned and structured experience. The 20-month training program is an inter-sequential integration of didactic and practical learning through classroom lectures, clinical laboratories, supplementary lectures, discussions, demonstrations, and supervised practice of standardized procedures. All clinical affiliates offer a balanced education sufficient in quantity and variety of general radiography examinations as well as diversified modern equipment. All students will have an opportunity to observe in interventional radiography, radiation therapy, nuclear medicine technology, computed tomography, diagnostic medical sonography, and magnetic resonance imaging. A standardized evaluation system is followed to document the student’s clinical progress throughout the program. All students are required to demonstrate competence in a variety of procedures and tasks. School faculty makes every effort to preserve educational cohesiveness without compromising the patient care responsibilities of the department. The program faculty has the right to make changes to the clinical assignment schedule if deemed necessary or advantageous. A student will never be expected to replace the registered technologist. Students will be scheduled at a specific clinical site. The schedule will be given in advance so students can plan accordingly. The rotations will be equally distributed. Changes can be made by program faculty due to extenuating circumstances. Program faculty schedules each student to practice individually with a certified radiologic technologist (RT) to ensure direct or indirect supervision. An RT is present in the x-ray room during student performance of a procedure or task. The RT will assess patient condition in relation to student knowledge and assist as needed throughout the exam. Direct supervision is required: ▪ Until the student proves competent on a particular procedure or task ▪ During performance of a competency evaluation ▪ During repeat images ▪ During RIMI rotations
Sample 1
Clinical Practicum. School is committed to excellence by meeting the educational needs of students and the healthcare community. School shall be responsible for the development, implementation, and operation of the clinical component of its educational programs offered and conducted at the Facility pursuant to this Agreement (collectively referred to herein as the “Practicum”). Such responsibilities of School include the following: a. Maintain responsibility for the educational curriculum and learning environment for Students including providing practical instruction to Students prior to their clinical assignments at the Facility; b. Assign to the Facility only those Students who have satisfactorily completed the prerequisites for clinical experience; c. Determine by mutual consent of the Facility and School the dates and times for Student placement and School must notify the Facility in advance of its planned schedule of Student assignments, including the dates of assignments, number of Students participating, and type of educational experience expected; d. Acquaint Facility personnel with the overall objectives of the School and provide the appropriate educational objectives and documents for clinical experiences to Facility.
Sample 1
AutoNDA by SimpleDocs

Related to Clinical Practicum

  • Ethical Practices 25.1. The Company, their respective employees, agents and their consultants and each other person acting for, or on behalf of, the Company, has complied with the United Kingdom Bribery Act, 2010 (the “UKBA”), FCPA, Prevention of Corruption Act, 1988 (the “PCA”) and all other Applicable Laws regarding illegal payments and gratuities (collectively with the UKBA, PCA and the FCPA referred as the “Improper Payment Laws”). The Founders and/or the Company, are not under investigation with respect to and have not been given notice of, any violation of any Improper Payment Laws applicable to the Business of the Company, as presently conducted or as has been conducted. 25.2. Neither the Company nor any of the Company’s directors, officers, employees or agents have, directly or indirectly, made, offered, promised or authorized any payment or gift of any money or anything of value to or for the benefit of any “foreign official” (as such term is defined in FCPA), foreign political party or official thereof or candidate for foreign political office for the purpose of (i) influencing any official act or decision of such official, party or candidate, (ii) inducing such official, party or candidate to use his, her or its influence to affect any act or decision of a foreign governmental authority, or (iii) securing any improper advantage, in the case of (i), (ii) and (iii) above in order to assist the Company or any of its affiliates in obtaining or retaining business for or with, or directing business to, any person. 25.3. Neither the Company nor any officer, director, agent or employee purporting to act on behalf of the Company or any other related party has at any time, directly or indirectly: (i) made, provided or paid any unlawful contributions, gifts, entertainment or other unlawful expenses to any candidate for political office, or failed to disclose fully any such contributions in violation of any Applicable Law; (ii) made any payment to any local, state, federal or any other type of governmental officer or official, or other person charged with similar public or quasi-public duties, other than payments required or allowed by Applicable Law (including without limitation, the FCPA, as amended); (iii) made any payment to any agent, employee, officer or director of any entity with which the Company or any other related party does business for the purpose of influencing such agent, employee, officer or director to do business with the Company or any Related Party; (iv) engaged in any transaction, maintained any bank account or used any corporate fund, except for transactions, bank accounts and funds which have been and are reflected in the normally maintained books and records of the Company and/or any other related party; (v) violated any provision of the FCPA, as amended; (vi) violated any provision of the UKBA, as amended; (vii) violated any provision of PCA, as amended; or (viii) made any payment in the nature of criminal bribery or any other unlawful payment. 25.4. Neither the Company nor any of its directors, officers, employees or agents have made or authorized any bribe, rebate, payoff, influence payment, kickback or other unlawful payment of funds or received or retained any funds in violation of any law, rule or regulation. 25.5. Neither the Company, or to the Company’s knowledge, any of its officers, directors or employees are the subject of any allegation, voluntary disclosure, investigation, prosecution, or other enforcement action related to the FCPA or any other anti-corruption law (collectively, “Enforcement Action”)

  • Professional Practice Professional practice varies with the range of duties and responsibilities appropriately assigned to the position (as outlined in 19.2 to 19.5)

  • Commercial Practices Borrower assumes all risks of the acts or omissions of any LC Beneficiary or transferees of any Letter of Credit with respect to the use of such Letter of Credit. Borrower agrees that neither any LC Issuing Bank, Administrative Agent nor any Lender (nor any of their respective directors, officers, or employees) shall be liable or responsible for: (a) the use which may be made of any Letter of Credit or for any acts or omissions of any LC Beneficiary or transferee in connection therewith; (b) any reference which may be made to this Agreement or to any Letter of Credit in any agreements, instruments or other documents; (c) the validity, sufficiency or genuineness of documents other than the Letters of Credit, or of any endorsement(s) thereon, even if such documents should in fact prove to be in any or all respects invalid, insufficient, fraudulent or forged or any statement therein proved to be untrue or inaccurate in any respect whatsoever; (d) payment by any LC Issuing Bank against presentation of documents which do not strictly comply with the terms of the applicable Letter of Credit, including failure of any documents to bear any reference or adequate reference to such Letter of Credit; or (e) any other circumstances whatsoever in making or failing to make payment under any Letter of Credit, except only that an LC Issuing Bank shall be liable to Borrower for acts or events described in clauses (a) through (e) above, to the extent, but only to the extent, of any direct damages, as opposed to indirect, special or consequential damages, suffered by Borrower which Borrower proves were caused by (i) any LC Issuing Bank’s willful misconduct or gross negligence in determining whether a drawing made under the applicable Letter of Credit complies with the terms and conditions therefor stated in such Letter of Credit or (ii) any LC Issuing Bank’s willful failure to pay under any Letter of Credit after a drawing by the respective LC Beneficiary strictly complying with the terms and conditions of the applicable Letter of Credit. Without limiting the foregoing, any LC Issuing Bank may accept any document that appears on its face to be in order, without responsibility for further investigation. Borrower hereby waives any right to object to any payment made under a Letter of Credit with regard to a drawing that is in the form provided in such Letter of Credit but which varies with respect to punctuation (except punctuation with respect to any Dollar amount specified therein), capitalization, spelling or similar matters of form.

  • Clinical 1.1 Provides comprehensive evidence based nursing care and individual case management to a specific group of patients/clients including assessment, intervention and evaluation. 1.2 Undertakes clinical shifts at the direction of senior staff and the Nursing Director including participation on the on-call/after-hours/weekend roster if required. 1.3 Responsible and accountable for patient safety and quality of care through planning, coordinating, performing, facilitating, and evaluating the delivery of patient care relating to a particular group of patients, clients or staff in the practice setting. 1.4 Monitors, reviews and reports upon the standard of nursing practice to ensure that colleagues are working within the scope of nursing practice, following appropriate clinical pathways, policies, procedures and adopting a risk management approach in patient care delivery. 1.5 Participates in xxxx rounds/case conferences as appropriate. 1.6 Educates patients/carers in post discharge management and organises discharge summaries/referrals to other services, as appropriate. 1.7 Supports and liaises with patients, carers, colleagues, medical, nursing, allied health, support staff, external agencies and the private sector to provide coordinated multidisciplinary care. 1.8 Completes clinical documentation and undertakes other administrative/management tasks as required. 1.9 Participates in departmental and other meetings as required to meet organisational and service objectives. 1.10 Develops and seeks to implement change utilising expert clinical knowledge through research and evidence based best practice. 1.11 Monitors and maintains availability of consumable stock. 1.12 Complies with and demonstrates a positive commitment to Regulations, Acts and Policies relevant to nursing including the Code of Ethics for Nurses in Australia, the Code of Conduct for Nurses in Australia, the National Competency Standards for the Registered Nurse and the Poisons Act 2014 and Medicines and Poisons Regulations 2016. 1.13 Promotes and participates in team building and decision making. 1.14 Responsible for the clinical supervision of nurses at Level 1 and/or Enrolled Nurses/ Assistants in Nursing under their supervision.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Research Project The findings of any research project, which would change the provisions of this Agreement will not be implemented until such changes are negotiated and agreed to by the parties.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Commercialization Reports Throughout the term of this Agreement and during the Sell-Off Period, and within thirty (30) days of December 31st of each year, Company will deliver to University written reports of Company’s and Sublicensees’ efforts and plans to develop and commercialize the innovations covered by the Licensed Rights and to make and sell Licensed Products. Company will have no obligation to prepare commercialization reports in years where (a) Company delivers to University a written Sales Report with active sales, and (b) Company has fulfilled all Performance Milestones. In relation to each of the Performance Milestones each commercialization report will include sufficient information to demonstrate achievement of those Performance Milestones and will set out timeframes and plans for achieving those Performance Milestones which have not yet been met.

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!